Infliximab is a monoclonal antibody that targets tumor necrosis factor alpha (TNFα), a key cytokine in chronic inflammatory diseases. By binding to both soluble and membrane-bound forms of TNFα, infliximab blocks its interaction with receptors, reducing inflammation and immune activation. This leads to decreased cytokine production, reduced migration of immune cells to inflamed tissues, and lower activity of tissue-degrading enzymes. It has shown effectiveness in various cell types, including fibroblasts, endothelial cells, and immune cells.
Because biologic medicines like infliximab are complex proteins made using recombinant technology, their monitoring and regulation are essential. Therapeutic drug monitoring (TDM) is often employed to ensure proper dosing, compliance, and safety. With the expiration of exclusivity for early biologics, biosimilars—highly similar versions of these biologics—are being developed. However, due to the intricacy of manufacturing processes, exact copies cannot be produced, and small differences may affect immunogenicity, pharmacokinetics, and patient response. This makes careful evaluation of biosimilars’ safety and efficacy critical in clinical practice.
This product is manufactured in Canada by Matriks Biotek.
| Size | 1 x 96 Well |
| Sensitivity | 156 ng/mL |
| Dynamic Range | cut off |
| Incubation Time | 95 minutes |
| Sample Type | Serum, Plasma |
| Storage | 2-8°C |